ArticleIndian journal of ophthalmology2022
The economic and social costs of visual impairment and blindness in India.
Article in Indian journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- The case for investment in eye health: systematic review and economic modelling analysis.Bulletin of the World Health Organization · 2023Pooled it
- Benefit-cost analysis of nonprofit cataract surgery services in Latin America: a multinational evaluation through an SROI lens.Cost effectiveness and resource allocation : C/E · 2026Article
- The social and economic burden of retinopathy of prematurity: screening, treatment, and health policy perspectives in a transnational narrative review.Frontiers in pediatrics · 2026Review
- Clinicodemographic Profile of Visual Disability Among Applicants for Disability Certification in South India.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Assessment of visual impairment and need of rehabilitation services for children attending schools for blind in an urban city of North India.Journal of family medicine and primary care · 2024Article
- Measuring utility values of eye conditions among children in India using the EQ-5D-Y instrument.Health economics review · 2024Article
- Article
- Vision and hearing problems and psychosocial outcomes: longitudinal evidence from the German Ageing Survey.Social psychiatry and psychiatric epidemiology · 2024Article
- Strategies for cataract and uncorrected refractive error case finding in India: Costs and cost-effectiveness at scale.The Lancet regional health. Southeast Asia · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To provide a current estimate of the economic and social costs (or welfare costs) of visual impairment and blindness in India. Methods: Using evidence from the recently conducted Blindness and Visual Impairment Survey across India, the Lancet Global Health Commission on Global Eye Health and other sources, we developed an economic model that estimates the costs of reduced employment, elevated mortality risk, education loss for children, productivity loss in employment, welfare loss for the unemployed, and caregiver costs associated with moderate and severe visual impairment (MSVI) and blindness. Probabilistic sensitivity analyses were also conducted by varying key parameters simultaneously. Results: The costs of MSVI and blindness in India in 2019 are estimated at INR 1,158 billion (range: INR 947-1,427 billion) or $54.4 billion at purchasing power parity exchange rates (range: $44.5-67.0 billion), accounting for all six cost streams. The largest cost was for the loss of employment, whereas the the second largest cost was for caregiver time. A more conservative estimate focusing only on employment loss and elevated mortality risk yielded a cost of INR 504 billion (range: INR 348-621 billion) or $23.7 billion (range: $16.3-29.2 billion). Conclusion: Poor eye health imposes a non-trivial recurring cost to the Indian economy equivalent to 0.47% to 0.70% of GDP in the primary scenario, a substantial constraint on the country's growth aspirations. Furthermore, the absolute costs of poor eye health will increase over time as India ages and becomes wealthier unless further progress is made in reducing the prevalence of MSVI and blindness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.